Barclays’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $296M | Sell |
5,145,086
-274,121
| -5% | -$15.7M | 0.06% | 219 |
|
|
2026
Q1 | $329M | Sell |
5,419,207
-1,899,064
| -26% | -$111M | 0.08% | 189 |
|
|
2025
Q4 | $395M | Sell |
7,318,271
-1,818,809
| -20% | -$87.5M | 0.09% | 162 |
|
|
2025
Q3 | $412M | Sell |
9,137,080
-184,510
| -2% | -$8.62M | 0.09% | 154 |
|
|
2025
Q2 | $431M | Buy |
9,321,590
+941,290
| +11% | +$46.2M | 0.1% | 127 |
|
|
2025
Q1 | $511M | Buy |
8,380,300
+3,741,262
| +81% | +$218M | 0.14% | 104 |
|
|
2024
Q4 | $262M | Sell |
4,639,038
-2,192,852
| -32% | -$123M | 0.07% | 176 |
|
|
2024
Q3 | $353M | Sell |
6,831,890
-304,244
| -4% | -$14.3M | 0.09% | 153 |
|
|
2024
Q2 | $296M | Buy |
7,136,134
+1,039,741
| +17% | +$46.5M | 0.09% | 166 |
|
|
2024
Q1 | $331M | Sell |
6,096,393
-746,516
| -11% | -$38M | 0.11% | 146 |
|
|
2023
Q4 | $351M | Buy |
6,842,909
+1,374,120
| +25% | +$72.1M | 0.13% | 124 |
|
|
2023
Q3 | $317M | Sell |
5,468,789
-688,768
| -11% | -$42.2M | 0.2% | 100 |
|
|
2023
Q2 | $394M | Buy |
6,157,557
+2,098,933
| +52% | +$141M | 0.25% | 80 |
|
|
2023
Q1 | $281M | Sell |
4,058,624
-545,302
| -12% | -$38.5M | 0.13% | 95 |
|
|
2022
Q4 | $331M | Buy |
4,603,926
+658,936
| +17% | +$49.7M | 0.15% | 104 |
|
|
2022
Q3 | $280M | Buy |
3,944,990
+122,980
| +3% | +$8.92M | 0.31% | 67 |
|
|
2022
Q2 | $294M | Sell |
3,822,010
-1,196,819
| -24% | -$91.2M | 0.18% | 76 |
|
|
2022
Q1 | $367M | Sell |
5,018,829
-2,245,605
| -31% | -$151M | 0.29% | 70 |
|
|
2021
Q4 | $453M | Buy |
7,264,434
+254,904
| +4% | +$15M | 0.17% | 110 |
|
|
2021
Q3 | $415M | Buy |
7,009,530
+2,344,458
| +50% | +$154M | 0.19% | 86 |
|
|
2021
Q2 | $312M | Buy |
4,665,072
+661,754
| +17% | +$43.2M | 0.15% | 110 |
|
|
2021
Q1 | $253M | Buy |
4,003,318
+856,053
| +27% | +$53.3M | 0.14% | 117 |
|
|
2020
Q4 | $195M | Buy |
3,147,265
+210,271
| +7% | +$12.9M | 0.1% | 149 |
|
|
2020
Q3 | $177M | Buy |
2,936,994
+338,693
| +13% | +$20.4M | 0.11% | 144 |
|
|
2020
Q2 | $153M | Buy |
2,598,301
+241,711
| +10% | +$14.5M | 0.12% | 127 |
|
|
2020
Q1 | $131M | Sell |
2,356,590
-2,690,542
| -53% | -$164M | 0.1% | 131 |
|
|
2019
Q4 | $324M | Buy |
5,047,132
+1,501,786
| +42% | +$86M | 0.18% | 92 |
|
|
2019
Q3 | $180M | Sell |
3,545,346
-212,568
| -6% | -$9.99M | 0.11% | 139 |
|
|
2019
Q2 | $170M | Sell |
3,757,914
-69,378
| -2% | -$3.23M | 0.1% | 165 |
|
|
2019
Q1 | $183M | Buy |
3,827,292
+1,338,565
| +54% | +$66.7M | 0.13% | 126 |
|
|
2018
Q4 | $129M | Sell |
2,488,727
-544,598
| -18% | -$29.3M | 0.1% | 144 |
|
|
2018
Q3 | $188M | Sell |
3,033,325
-3,445,486
| -53% | -$204M | 0.13% | 109 |
|
|
2018
Q2 | $359M | Buy |
6,478,811
+2,538,241
| +64% | +$137M | 0.31% | 47 |
|
|
2018
Q1 | $249M | Buy |
3,940,570
+1,271,252
| +48% | +$81.8M | 0.19% | 87 |
|
|
2017
Q4 | $164M | Buy |
2,669,318
+777,696
| +41% | +$48.6M | 0.13% | 128 |
|
|
2017
Q3 | $121M | Buy |
1,891,622
+118,572
| +7% | +$6.92M | 0.12% | 137 |
|
|
2017
Q2 | $98.8M | Buy |
1,773,050
+279,208
| +19% | +$15.2M | 0.11% | 144 |
|
|
2017
Q1 | $81.2M | Buy |
1,493,842
+176,954
| +13% | +$9.71M | 0.09% | 167 |
|
|
2016
Q4 | $77M | Sell |
1,316,888
-28,737
| -2% | -$1.57M | 0.08% | 186 |
|
|
2016
Q3 | $72.6M | Buy |
1,345,625
+429,713
| +47% | +$27.6M | 0.08% | 182 |
|
|
2016
Q2 | $67.4M | Buy |
915,912
+290,737
| +47% | +$20.5M | 0.09% | 188 |
|
|
2016
Q1 | $39.4M | Sell |
625,175
-69,732
| -10% | -$4.4M | 0.06% | 272 |
|
|
2015
Q4 | $47.3M | Sell |
694,907
-989,848
| -59% | -$65.4M | 0.06% | 299 |
|
|
2015
Q3 | $99.4M | Buy |
1,684,755
+65,708
| +4% | +$4.17M | 0.12% | 139 |
|
|
2015
Q2 | $107M | Sell |
1,619,047
-412,041
| -20% | -$27.2M | 0.12% | 134 |
|
|
2015
Q1 | $130M | Sell |
2,031,088
-566,234
| -22% | -$35.4M | 0.15% | 113 |
|
|
2014
Q4 | $153M | Sell |
2,597,322
-263,730
| -9% | -$14.9M | 0.15% | 102 |
|
|
2014
Q3 | $146M | Buy |
2,861,052
+35,262
| +1% | +$1.76M | 0.14% | 99 |
|
|
2014
Q2 | $136M | Sell |
2,825,790
-651,158
| -19% | -$32.1M | 0.14% | 97 |
|
|
2014
Q1 | $177M | Buy |
3,476,948
+135,764
| +4% | +$7.22M | 0.2% | 76 |
|
|
2013
Q4 | $177M | Buy |
3,341,184
+1,233,705
| +59% | +$62.8M | 0.18% | 74 |
|
|
2013
Q3 | $96.9M | Buy |
2,107,479
+120,138
| +6% | +$5.27M | 0.12% | 123 |
|
|
2013
Q2 | $88.8M | Buy |
+1,987,341
| New | +$86.3M | 0.11% | 131 |
|
Other funds holding BMY
Barclays's BMY Position: Q2 2026 in Review
Barclays reduced its Bristol-Myers Squibb (BMY) stake by 5.1% in Q2 2026, selling an estimated $15.7M and leaving 5,145,086 shares worth $296M. The position accounts for 0.06% of the portfolio, ranked #219.
Barclays first reported a position in BMY in Q2 2013 and has held it in 53 quarters since. The position peaked at $511M in Q1 2025. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Barclays held 5,145,086 shares of Bristol-Myers Squibb worth $296M as of Q2 2026.
- Barclays sold 274,121 Bristol-Myers Squibb shares in Q2 2026, an estimated $15.7M.
- Bristol-Myers Squibb made up 0.06% of Barclays's portfolio in Q2 2026, its #219 holding.
- Barclays first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 53 quarters since.
- Barclays's Bristol-Myers Squibb position peaked at $511M in Q1 2025.
- 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.